[January 13, 2014]

Research and Markets: Global Ependymoma Clinical Trials Review Report - H2 2013 Edition

Research and Markets (http://www.researchandmarkets.com/research/fjskzb/ependymoma_global) has announced the addition of the "Ependymoma Global Clinical Trials Review, H2, 2013" report to their offering.

This report provides elemental information and data relating to the clinical trials on Ependymoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for reating Ependymoma.

Scope

• Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
• Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
• Listings of discontinued trials (suspended, withdrawn and terminated)
  

Top Companies Participating in Ependymoma Therapeutics Clinical Trials

• Advantagene, Inc.
• Astellas US Holding, Inc.
• Burzynski Research Institute, Inc.
• DNAtrix, Inc.
• Direct Therapeutics, Inc.
• Eli Lilly and Company

Clinical Trial Overview of Top Institutes / Government

• National Cancer Institute
• St. Jude Children's Research Hospital, Inc.
• Children's Oncology Group
• The University of Texas M. D. Anderson Cancer Center
• City of Hope National Medical Center
• Children's Cancer and Leukaemia Group
• Massachusetts General Hospital
• Northwestern University
• Cancer Research UK
• Memorial Sloan Kettering Cancer Center
  

For more information visit http://www.researchandmarkets.com/research/fjskzb/ependymoma_global

[ Back To TMCnet.com's Homepage ]